Business Context and Reporting Period
This Form 8-K was filed by NanoVibronix, Inc. (trading symbol: NAOV) on December 14, 2020, reporting events occurring on December 10, 2020. The Company, an emerging growth corporation incorporated in Delaware, operates in the medical device sector, specifically focusing on PainShield devices for pain management.
Key Financial Metrics
This filing does not contain standard financial statements, revenue figures, profit margins, cash flow data, or debt levels. The only financial metric disclosed relates to the commercial terms of a new agreement:
- Revenue Target: The amended agreement increases the minimum purchase requirement from an initial target of $1.1 million over two years to $7.8 million over three years.
- Up-front Payment: The Purchaser paid an up-front licensing fee, though the specific amount is not disclosed in this text.
Material Changes
The primary material change is the execution of an Amended and Restated Distribution Agreement with Ultra Pain Products Inc. on December 10, 2020. Key changes include:
- Expanded Rights: The Purchaser now holds exclusive rights to sell "Private Labeled" versions of the PainShield devices in the United States, manufactured to the Purchaser's specifications.
- Customer Protection: The Purchaser is granted exclusive rights to sell to specific protected customers and end users for 12 months following the first sale.
- Manufacturing Restrictions: NanoVibronix agreed not to produce or authorize third parties to produce the Private Labeled Products.
- Increased Commitments: Minimum quarterly and yearly order requirements were significantly raised to support the new $7.8 million revenue target.
Outlook, Risks, and Contingencies
Agreement Terms: The agreement has an initial term expiring at the end of 2023, with automatic renewal options contingent on meeting minimum purchase requirements. Either party may terminate with 90 days' notice.
Termination Risks: NanoVibronix retains the right to unilaterally terminate the agreement if the Purchaser fails to meet minimum quarterly order requirements for two successive quarters or fails to meet the minimum yearly order requirement for one calendar year.
Management Commentary: The filing references a press release issued on December 11, 2020, but does not provide additional qualitative commentary on the strategic outlook beyond the terms of the agreement.
Investor Verification Checklist
- Verify the specific amount of the up-front licensing fee paid by Ultra Pain Products Inc.
- Confirm the exact quarterly and yearly minimum order thresholds required to avoid termination.
- Review the attached press release (Exhibit 99.1) for additional strategic context not included in the 8-K text.
- Monitor future filings to assess if the Purchaser meets the increased $7.8 million revenue target over the three-year term.